Document:

EXHIBIT 10.24

 

ESCROW DEPOSIT AGREEMENT

 

This ESCROW DEPOSIT AGREEMENT
(this “Agreement”) dated as of this __ day of _____2013, by and among MusclePharm Corporation, a Nevada corporation
(the “Company”), having an address at 4721 Ironton Street, Building A, Denver, CO 80239, GVC Capital LLC
(the “Placement Agent”), having an address at 5350 S. Roslyn St., Suite 400, Greenwood Village, Colorado
80111 and SIGNATURE BANK (the “Escrow Agent”), a New York State chartered bank, having an office at
950 Third avenue, 9th Floor, New York, NY 10022. All capitalized terms not herein defined shall have the meaning ascribed
to them in that certain Post-Effective Amendment No. 1 to Form S-1, as filed with the Securities and Exchange Commission on January
__, 2013 and as amended or supplemented from time-to-time, including all attachments, schedules and exhibits thereto.

 

 

W I T N E
S S E T H:

 

WHEREAS,
pursuant to the terms of Post-Effective Amendment No. 1 to Form S-1 the Company is offering to qualified investors on a “best
efforts” basis (the “Offering”) a maximum of 1,500,000.00 shares of the Company’s Series D Convertible
Preferred Stock (the “Securities”) for aggregate consideration of up to $13,200.00 (“Maximum Amount”).
Each Share is being sold at a price of $[ ] per Share; and

 

WHEREAS, unless
any Securities are sold by January 30th, 2013 (the “Termination Date”), or by February 28th,
2013 (the “Final Termination Date”) if the Termination Date has been extended by Company and the Placement Agent, the
Offering shall terminate and all funds shall be returned to the Investors in the Offering; and

 

WHEREAS, the
Company and Placement Agent desire to establish an escrow account with the Escrow Agent into which the Company and Placement Agent
shall instruct Investors introduced to the Company by Placement Agent (the “Investors”) to deposit checks and
other instruments for the payment of money made payable to the order of “Signature Bank as Escrow Agent for MusclePharm Corporation,”
and Escrow Agent is willing to accept said checks and other instruments for the payment of money in accordance with the terms hereinafter
set forth; and

 

WHEREAS, the
Company and Placement Agent represent and warrant to the Escrow Agent that they have not stated to any individual or entity that
the Escrow Agent’s duties will include anything other than those duties stated in this Agreement; and

 

WHEREAS, the
Company and Placement Agent warrant to the Escrow Agent that a copy of each document that has been delivered to Investors
and third parties that include Escrow Agent’s name and duties, has been attached hereto as Schedule I.

 

 

    	1

    	 

    

 

NOW, THEREFORE,
IT IS AGREED as follows:

 

1.          Delivery of Escrow Funds.

 

(a) Placement Agent and
the Company shall instruct Investors to deliver to Escrow Agent checks made payable to the order of “Signature Bank, as Escrow
Agent for MusclePharm Corporation,” or wire transfer to Signature Bank, 950 Third Avenue, 9th Floor, New York,
NY 10022, ABA No. 026013576 for credit to Signature Bank, as Escrow Agent for MusclePharm Corporation, Account No. _____________,
in each case, with the name, address and social security number or taxpayer identification number of the individual or entity making
payment. In the event any Subscriber’s address and/or social security number or taxpayer identification number are not provided
to Escrow Agent by the Subscriber, then Placement Agent and/or the Company agree to promptly provide Escrow Agent with such information
in writing. The checks or wire transfers shall be deposited into a non interest-bearing account at Signature Bank entitled “Signature
Bank, as Escrow Agent for MusclePharm Corporation” (the “Escrow Account”).

 

(b)          The collected
funds deposited into the Escrow Account are referred to as the “Escrow Funds.”

 

(c)          The Escrow Agent
shall have no duty or responsibility to enforce the collection or demand payment of any funds deposited into the Escrow Account.
If, for any reason, any check deposited into the Escrow Account shall be returned unpaid to the Escrow Agent, the sole duty of
the Escrow Agent shall be to return the check to the Subscriber and advise the Company and Placement Agent promptly thereof.

 

2.          Release of Escrow Funds. The
Escrow Funds shall be paid by the Escrow Agent in accordance with the following:

 

(a)          In the event
that the Company and Placement Agent advise the Escrow Agent in writing that the Offering has been terminated (the “Termination
Notice”), the Escrow Agent shall promptly return the funds paid by each Subscriber to said Subscriber without interest
or offset.

 

(b) If prior to 3:00
P.M. Eastern time on the Termination Date, the Escrow Agent receives written notice, in the form of Exhibit A, attached hereto
and made a part hereof, and signed by the Company and Placement Agent, stating that the Termination Date has been extended to the
Final Termination Date, then the Termination Date shall be so extended.           

 

(c) Provided that the
Escrow Agent does not receive the Termination Notice in accordance with paragraph 2(a) and there are any funds deposited into the
Escrow Account on or prior to later of the Termination Date or the date stated in the Extension Notice, if any, received by the
Escrow Agent in accordance with paragraph 2(b) above, the Escrow Agent shall, upon receipt of written instructions, in the form
of Exhibit B, attached hereto and made a part hereof, or in a form and substance satisfactory to the Escrow Agent, received from
the Company and Placement Agent, pay the Escrow Funds in accordance with such written instructions, such payment or payments to
be made by wire transfer within one (1) business day of receipt of such written instructions. Such instructions must be received
by the Escrow Agent no later than 3:00 PM Eastern Time on a Banking Day for the Escrow Agent to process such instructions that
Banking Day.

 

    	2

    	 

    
 

 

(d)          If by 3:00 P.M.
Eastern time on the later of the Termination Date or the date stated in the Extension Notice, if any, that the Escrow Agent has
received in accordance with paragraph 2(b) above, the Escrow Agent has not received written instructions from the Company and Placement
Agent regarding the disbursement of the Escrow Funds, then the Escrow Agent shall promptly return the Escrow Funds to the Investors
without interest or offset. The Escrow Funds returned to each Subscriber shall be free and clear of any and all claims of the Escrow
Agent.

 

(e)          The Escrow Agent
shall not be required to pay any uncollected funds or any funds that are not available for withdrawal.

 

(f)          If the Termination
Date, Final Termination Date or any date that is a deadline under this Agreement for giving the Escrow Agent notice or instructions
or for the Escrow Agent to take action is not a Banking Day, then such date shall be the Banking Day that immediately preceding
that date. A Banking Day is any day other than a Saturday, Sunday or a day that a New York State chartered bank is not legally
obligated to be opened.

 

3.          Acceptance by Escrow Agent.
The Escrow Agent hereby accepts and agrees to perform its obligations hereunder, provided that:

 

(a)          The Escrow Agent
may act in reliance upon any signature believed by it to be genuine, and may assume that any person who has been designated by
Placement Agent or the Company to give any written instructions, notice or receipt, or make any statements in connection with the
provisions hereof has been duly authorized to do so. Escrow Agent shall have no duty to make inquiry as to the genuineness, accuracy
or validity of any statements or instructions or any signatures on statements or instructions. The names and true signatures of
each individual authorized to act singly on behalf of the Company and Placement Agent are stated in Schedule II, which is
attached hereto and made a part hereof. The Company and Placement Agent may each remove or add one or more of its authorized signers
stated on Schedule II by notifying the Escrow Agent of such change in accordance with this Agreement, which notice shall include
the true signature for any new authorized signatories.

 

 

(b)          The Escrow Agent
may act relative hereto in reliance upon advice of counsel in reference to any matter connected herewith. The Escrow Agent shall
not be liable for any mistake of fact or error of judgment or law, or for any acts or omissions of any kind, unless caused by its
willful misconduct or gross negligence.

 

(c)          Placement Agent
and the Company agree to indemnify and hold the Escrow Agent harmless from and against any and all claims, losses, costs, liabilities,
damages, suits, demands, judgments or expenses (including but not limited to reasonable attorney’s fees) claimed against
or incurred by Escrow Agent arising out of or related, directly or indirectly, to this Escrow Agreement unless caused by the Escrow
Agent’s gross negligence or willful misconduct.

 

    	3

    	 

    
 

(d)          In the event
that the Escrow Agent shall be uncertain as to its duties or rights hereunder, the Escrow Agent shall be entitled to (i) refrain
from taking any action other than to keep safely the Escrow Funds until it shall be directed otherwise by a court of competent
jurisdiction, or (ii) deliver the Escrow Funds to a court of competent jurisdiction.

 

(e)          The Escrow Agent
shall have no duty, responsibility or obligation to interpret or enforce the terms of any agreement other than Escrow Agent’s
obligations hereunder, and the Escrow Agent shall not be required to make a request that any monies be delivered to the Escrow
Account, it being agreed that the sole duties and responsibilities of the Escrow Agent shall be to the extent not prohibited by
applicable law (i) to accept checks or other instruments for the payment of money and wire transfers delivered to the Escrow Agent
for the Escrow Account and deposit said checks and wire transfers into the non-interest bearing Escrow Account, and (ii) to disburse
or refrain from disbursing the Escrow Funds as stated above, provided that the checks received by the Escrow Agent have been collected
and are available for withdrawal.

 

4.          Escrow Account Statements and
Information. The Escrow Agent agrees to send to the Company and/or the Placement Agent a
copy of the Escrow Account periodic statement, upon request in accordance with the Escrow Agent’s regular practices
for providing account statements to its non-escrow clients and to also provide the Company and/or Placement
Agent, or their designee, upon request other deposit account information, including Account balances, by telephone or by computer
communication, to the extent practicable. The Company and Placement Agent agree to complete and sign all forms or agreements required
by the Escrow Agent for that purpose. The Company and Placement Agent each consent to the Escrow Agent’s release of such
Account information to any of the individuals designated by Company or Placement Agent, which designation has been signed in accordance
with paragraph 3(a) by any of the persons in Schedule II.  Further, the Company and Placement Agent have an option to receive
e-mail notification of incoming and outgoing wire transfers. If this e-mail notification service is requested and subsequently
approved by the Escrow Agent, the Company and Placement Agent agrees to provide a valid e-mail address and other information necessary
to set-up this service and sign all forms and agreements required for such service. The Company
and Placement Agent each consent to the Escrow Agent’s release of wire transfer information to the designated e-mail address(es).
The Escrow Agent’s liability for failure to comply with this section shall not exceed the cost of providing such information.

 

5.          Resignation and Termination of
the Escrow Agent. The Escrow Agent may resign at any time by giving 30 days’ prior written notice of such resignation
to Placement Agent and the Company. Upon providing such notice, the Escrow Agent shall have no further obligation hereunder except
to hold as depositary the Escrow Funds that it receives until the end of such 30-day period. In such event, the Escrow Agent shall
not take any action, other than receiving and depositing Investors checks and wire transfers in accordance with this Agreement,
until the Company has designated a banking corporation, trust company, attorney or other person as successor. Upon receipt of such
written designation signed by Placement Agent and the Company, the Escrow Agent shall promptly deliver the Escrow Funds to such
successor and shall thereafter have no further obligations hereunder. If such instructions are not received within 30 days following
the effective date of such resignation, then the Escrow Agent may deposit the Escrow Funds held by it pursuant to this Agreement
with a clerk of a court of competent jurisdiction pending the appointment of a successor. In either case provided for in this paragraph,
the Escrow Agent shall be relieved of all further obligations and released from all liability thereafter arising with respect to
the Escrow Funds.

 

    	4

    	 

    
 

5.          Termination. The Company and
Placement Agent may terminate the appointment of the Escrow Agent hereunder upon written notice specifying the date upon which
such termination shall take effect, which date shall be at least 30 days from the date of such notice. In the event of such termination,
the Company and Placement Agent shall, within 30 days of such notice, appoint a successor escrow agent and the Escrow Agent shall,
upon receipt of written instructions signed by the Company and Placement Agent, turn over to such successor escrow agent all of
the Escrow Funds; provided, however, that if the Company and Placement Agent fail to appoint a successor escrow agent
within such 30-day period, such termination notice shall be null and void and the Escrow Agent shall continue to be bound by all
of the provisions hereof. Upon receipt of the Escrow Funds, the successor escrow agent shall become the escrow agent hereunder
and shall be bound by all of the provisions hereof and Signature Bank shall be relieved of all further obligations and released
from all liability thereafter arising with respect to the Escrow Funds and under this Agreement.

 

6.          Investment. All funds received
by the Escrow Agent shall be invested only in non-interest bearing bank accounts at Signature Bank.

 

7.          Compensation.
Escrow Agent shall be entitled, for the duties to be performed by it hereunder, to a fee of $3,500, which fee shall be paid
by the Company upon the signing of this Agreement. In addition, the Company shall be obligated to reimburse
Escrow Agent for all fees, costs and expenses incurred or that become due in connection with this Agreement or the Escrow Account,
including reasonable attorney’s fees. Neither the modification, cancellation, termination or rescission of this Agreement
nor the resignation or termination of the Escrow Agent shall affect the right of Escrow Agent to retain the amount of any fee which
has been paid, or to be reimbursed or paid any amount which has been incurred or becomes due, prior to the effective date of any
such modification, cancellation, termination, resignation or rescission. To the extent the Escrow Agent has incurred any such expenses,
or any such fee becomes due, prior to any closing, the Escrow Agent shall advise the Company and the Company shall direct all such
amounts to be paid directly at any such closing.

 

8.          Notices. All notices, requests,
demands and other communications required or permitted to be given hereunder shall be in writing and shall be deemed to have been
duly given if sent by hand-delivery, by facsimile (followed by first-class mail), by nationally recognized overnight courier service
or by prepaid registered or certified mail, return receipt requested, to the addresses set forth below:

 

    	5

    	 

    
 

If to Placement Agent:

 

GVC Capital LLC

5350
S. Roslyn St., Suite 400

Greenwood
Village, CO 8011

Attention:
Vicki D. E. Barone, Senior Managing Partner

Fax:
303-694-6287

 

 

 

If to the Company:

 

MusclePharm
Corporation

4721
Ironton Street Building A

Denver,
CO 80239

Attention:
Brad J. Pyatt, CEO

Fax:
800-450-7165

 

 

If to Escrow Agent:

 

Signature Bank

950 Third Avenue, 9th
Floor

New York, NY 10022

Attention: John D. Gonzalez

Fax: 646-822-1520

 

9.          General.

 

(a)          This
Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York applicable to agreements
made and to be entirely performed within such State, without regard to choice of law principles and any action brought hereunder
shall be brought in the courts of the State of New York, located in the County of New York. Each party hereto irrevocably waives
any objection on the grounds of venue, forum nonconveniens or any similar grounds and irrevocably consents to service of process
by mail or in any manner permitted by applicable law and consents to the jurisdiction of said courts. Each of the parties hereto
hereby waives all right to trial by jury in any action, proceeding or counterclaim arising out of the transactions contemplated
by this Agreement.

 

(b)          This Agreement
sets forth the entire
agreement and understanding of the parties with respect to the matters contained herein and supersedes all prior agreements, arrangements
and understandings relating thereto.

 

    	6

    	 

    
 

 

(c)          All of the terms
and conditions of this Agreement shall be binding upon, and inure to the benefit of and be enforceable by, the parties hereto,
as well as their respective successors and assigns.

 

(d)          This Agreement
may be amended, modified, superseded or canceled, and any of the terms or conditions hereof may be waived, only by a written instrument
executed by each party hereto or, in the case of a waiver, by the party waiving compliance. The failure of any party at any time
or times to require performance of any provision hereof shall in no manner affect its right at a later time to enforce the same.
No waiver of any party of any condition, or of the breach of any term contained in this Agreement, whether by conduct or otherwise,
in any one or more instances shall be deemed to be or construed as a further or continuing waiver of any such condition or breach
or a waiver of any other condition or of the breach of any other term of this Agreement. No party may assign any rights, duties
or obligations hereunder unless all other parties have given their prior written consent.

 

(e)          If any provision
included in this Agreement proves to be invalid or unenforceable, it shall not affect the validity of the remaining provisions.

 

(f)          This Agreement
and any modification or amendment of this Agreement may be executed in several counterparts or by separate instruments and all
of such counterparts and instruments shall constitute one agreement, binding on all of the parties hereto.

 

10.          Form of Signature. The parties hereto agree to
accept a facsimile transmission copy of their respective actual signatures as evidence of their actual signatures to this Agreement
and any modification or amendment of this Agreement; provided, however, that each party who produces a facsimile
signature agrees, by the express terms hereof, to place, promptly after transmission of his or her signature by fax, a true and
correct original copy of his or her signature in overnight mail to the address of the other party.

 

    	7

    	 

    

IN WITNESS WHEREOF, the parties
have duly executed this Agreement as of the date first set forth above.

 

	MusclePharm Corporation 	 	GVC Capital LLC	 
	 	 	 	 	 	 
	By:		 	By:		 
	 	Name:	 	 	Name:	 
	 	Title:	 	 	Title:	 

 

 

 

SIGNATURE BANK

 

 

	By:		 
	 	Name:	 
	 	Title:	 
	 	 	 
	 	 	 
	By:		 
	 	Name:	 
	 	Title:	 

 

 

 

 

 

 

    	8

    	 

    

Schedule
I

OFFERING DOCUMENTS

 

 

 

 

 

 

    	 

    	 

    

Schedule
II

 

The Escrow Agent is
authorized to accept instructions signed or believed by the Escrow Agent to be signed by any one of the following on behalf of
the Company and Placement Agent.

 

          MusclePharm Corporation

 

	Name	 	True Signature
	 	 	 
	 	 	  

 

 

GVC Capital LLC

 

	Name	 	True Signature
	 	 	 
		 	
	 	 	 
		 	

 

 

 

 

 

    	 

    	 

    

Exhibit A

Extension Notice

 

 

 

 

 

Date: __________________

 

 

 

Signature Bank

950 Third Avenue, 9th Floor

New York, NY 10022

Attention: John D. Gonzalez

 

 

 

 

Dear _________:

 

In accordance with
the terms of paragraph 2(b) of an Escrow Deposit Agreement dated ___ _______, by and among MusclePharm Corporation (the “Company”),
GVC Capital LLC (“Placement Agent”), and Signature Bank (the “Escrow Agent”), the Company and Placement
Agent hereby notify the Escrow Agent that the Termination Date has been extended to February 28, 2013, the Final Termination Date.

 

Very truly yours,

 

MusclePharm Corporation

By:_____________

Name:__________

Title:____________

 

GVC Capital LLC

By:_____________

Name:___________

Title:____________

 

 

 

 

 

    	 

    	 

    

Exhibit B

 

FORM OF ESCROW RELEASE NOTICE

 

Date:

 

Signature Bank

950 Third Avenue, 9th Floor

New York, NY 10022

Attention: John D. Gonzalez

 

Dear _________:

 

In accordance with the terms of paragraph 2(c) of an Escrow
Deposit Agreement dated as of ________ __, 2013 (the "Escrow Agreement"), by and between MusclePharm Corporation (the
"Company"), Signature Bank (the "Escrow Agent") and GVC Capital LLC ("Placement Agent"), the Company
and Placement Agent hereby notify the Escrow Agent that the ________ closing will be held on ___________ for gross proceeds of
$_________.

 

 

PLEASE DISTRIBUTE FUNDS BY WIRE TRANSFER AS FOLLOWS (wire instructions
attached):

 

 

	________________________:	$
	 	 
	________________________:	$
	 	 
	________________________:	$

 

 

Very truly yours,

 

MusclePharm Corporation

By:_____________

Name:__________

Title:____________

 

GVC Capital LLC

By:_____________

Name:___________

Title:____________EXHIBIT 10.25

 

Form of Subscription Agreement

 

This Subscription Agreement
(this “Agreement”) is dated as of [•] between MusclePharm Corporation, a Nevada corporation (the “Company”),
and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser”).

 

WHEREAS, subject to
the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act
(as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires
to purchase from the Company, securities of the Company as more fully described in this Agreement.

 

NOW, THEREFORE, in
consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

 

ARTICLE I.

 

DEFINITIONS

 

1.1. Definitions.  In
addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings
set forth in this Section 1.1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Board of
Directors” means the board of directors of the Company.

 

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.

 

“Closing”
means the closing of the purchase and sale of the Shares pursuant to Section 2.1.

 

“Closing Date”
means the third Trading Day following the date hereof or such other date as the Placement Agent and the Company may agree in writing,
in either case, on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and
all conditions precedent to (i) the Purchasers’ obligations to pay the Subscription Amount and (ii) the Company’s obligations
to deliver the Shares, in each case, have been satisfied or waived.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common Stock”
means the shares of the Company’s common stock, par value $0.001 per share.

 

“Escrow Agent” means
the Escrow Agent as defined in the Escrow Agreement.

 

“Escrow Agreement” means
Escrow Agreement dated ___________, between the Company, the Placement Agent and __________________.

 

    	 

    	 

    

 

“Exchange Act” means
the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Material
Adverse Effect” means (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document,
(ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company and its Subsidiary, taken as a whole, (iii) a material adverse effect on the Company’s ability to perform
in any material respect on a timely basis its obligations under any Transaction Document; or (iv) from the date hereof to the Closing
Date, trading in the Common Stock or quotation on the over the counter bulletin board shall not have been suspended by the Commission
or FINRA, trading in securities generally as reported by Bloomberg L/P. shall not have been suspended or limited, or minimum prices
shall not have been established on any Trading Market, nor shall a banking moratorium have been declared either by the United States
of New York State banking authorities. For the purpose of this Agreement, the terms Material Adverse Effect or material adverse
change shall not include any such effects resulting, directly or indirectly, from the filing of the Prospectus or the performance
of the transactions contemplated by, or pursuant to, the Placement Agent Agreement or this Agreement.

 

“Per Share
Purchase Price” equals $[•], subject to adjustment as provided in the Certificate of Designation for the Preferred
Shares that occur after the date of this Agreement and prior to the Closing.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Placement
Agent” means GVC Capital LLC.

 

“Preferred
Shares” means the shares of the Company’s Series D Convertible Preferred Stock, par value $0.001 per share, and
any other class of securities into which such securities may hereafter be reclassified or changed prior to the Closing. The terms
of the Preferred Shares will be set forth in a certificate of designation (the “Certificate of Designation”)
to be filed by the Company with the Secretary of State of the State of Nevada.

 

“Preliminary
Prospectus” means each prospectus used prior to the effectiveness of the Registration Statement, and each prospectus
that omitted the Rule 430A Information that was used after such effectiveness and prior to the execution and delivery of the Placement
Agency Agreement.

 

“Pricing
Prospectus” means the Preliminary Prospectus, subject to completion, dated [•], 2013, that was included in the
Registration Statement immediately prior to the Time of Sale.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.

 

“Prospectus”
means the final prospectus in the form first furnished to the Placement Agent for use in the Offering.

 

“Registration
Statement” means the effective registration statement on Form S-1 with Commission (file no. 333-184625) which registers
the sale of the Shares (including the shares of Common Stock issuable upon conversion thereof) to the Purchasers (including the
documents incorporated by reference therein, if any).

 

    	- 2 -

    	 

    

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Shares”
means the Preferred Shares issued or issuable to each Purchaser pursuant to this Agreement.

 

“Short Sales”
means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to
include the location and/or reservation of borrowable Ordinary Shares). 

 

“Subscription
Amount” means, as to each Purchaser, the aggregate amount to be paid for Shares hereunder as specified below on the signature
page of this Agreement in United States dollars and in immediately available funds.

 

“Subsidiary”
means Canada MusclePharm Enterprises Corp.

 

“Time of Sale”
with respect to any Purchaser, means the time of receipt and acceptance of an executed copy of this Agreement from such Purchaser.

 

“Trading Day”
means a day on which the principal Trading Market is open for trading.

 

“Trading Market”
means the principal trading market in the United States on which the shares of Common Stock are listed or quoted for trading on
the date in question.

 

“Transaction
Documents” means this Agreement, the Certificate of Designation and any other documents or
agreements executed in connection with the transactions contemplated hereunder.

 

“Transfer
Agent” means Corporate Stock Transfer, the current transfer agent of the Company, with a mailing address of 3200 Cherry
Creek Drive South, Suite 430, Denver, Colorado 80209 and a facsimile number of 303-282-5800, and any successor transfer agent of
the Company.

 

ARTICLE II.

 

PURCHASE AND SALE

 

2.1. Closing.  On
the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers,
severally and not jointly, agree to purchase, an aggregate of [•] Shares.  Each Purchaser shall deliver to the Company,
via wire transfer or a certified check, immediately available funds equal to such Purchaser’s Subscription Amount as set
forth on the signature page hereto executed by such Purchaser and the Company shall deliver to each Purchaser its respective Shares
as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section
2.2 deliverable at the Closing.  Upon satisfaction of the covenants and conditions set forth in Section 2.2 and Section
2.3, the Closing shall occur at the offices of Reed Smith LLP, counsel for the Placement Agent, located at 599 Lexington Avenue,
New York, NY 10104, or such other location as the parties shall mutually agree.

 

2.2. Deliveries.

 

(a) On or prior to
the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:

 

    	- 3 -

    	 

    

 

(i) this
Agreement duly executed by the Company;

 

(ii) a
copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis equal
to such Purchaser’s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser;

 

(iii) the
Pricing Prospectus and Prospectus (which may be delivered in accordance with Rule 172 under the Securities Act); and

 

(b) On or prior to the
Closing Date, each Purchaser shall deliver or cause to be delivered to the Company such Purchaser’s Subscription Amount by
wire transfer to the account designated in writing by the Company.

 

2.3. Closing
Conditions.

 

(a) The obligations
of the Company hereunder in connection with the Closing with respect to each Purchaser are subject to the following conditions
being met:

 

(i) the accuracy in all
material respects on the Closing Date of the representations and warranties of such Purchaser contained herein (unless as of a
specific date therein in which case they shall be accurate as of such date);

 

(ii) all obligations,
covenants and agreements of such Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and

 

(iii) the delivery by
such Purchaser of such Purchaser’s Subscription Amount.

 

(b) The respective
obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:

 

(i) the accuracy in all
material respects when made and on the Closing Date of the representations and warranties of the Company contained herein (unless
as of a specific date therein in which case they shall be accurate as of such date);

 

(ii) all obligations,
covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;

 

(iii) the delivery by
the Company of the items set forth in Section 2.2(a) of this Agreement; and

 

(iv) there shall have
been no Material Adverse Effect with respect to the Company since the date hereof.

 

2.4           Subscription
Agreements; Purchasers. The Company proposes to enter into subscription agreements in substantially the form of this Agreement
(collectively with this Agreement, the “Agreements”) with certain other investors (collectively with the Purchaser,
the “Purchasers”).

 

2.5           Placement
Agent. The Purchaser acknowledges that the Company has agreed to pay GVC Capital LLC (the “Placement
Agent”) in respect of the sales of the Shares to the Purchaser.

 

    	- 4 -

    	 

    

 

2.6           Escrow
Agreement. The Purchaser acknowledges that its Subscription Amount will be released by the Escrow Agent to the Company at the
Closing pursuant to the terms and conditions of the Escrow Agreement without any further instruction or consent from the Purchaser.
The Closing will occur upon satisfaction, in the judgment of the Company and the Placement Agent, of the conditions set forth in
Section 2.3 of this Agreement.

 

ARTICLE III.

 

REPRESENTATIONS AND WARRANTIES

 

3.1. Representations
and Warranties of the Company. The Company hereby represents and warrants to each Purchaser as follows. The following representations
and warranties also apply to the Subsidiary, whether so expressed or not, unless the context clearly requires otherwise.

 

(a) Organization,
Good Standing and Power; Subsidiaries.  The Company has been duly incorporated or organized, is validly existing
as a corporation or other legal entity in good standing (or the foreign equivalent thereof) under the laws of its jurisdiction
of incorporation and has the requisite corporate power to own, lease and operate its properties and assets and to conduct its business
as it is now being conducted.  The Company is duly qualified as a foreign corporation to do business and is in good standing
in every jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary
except for any jurisdiction(s) (alone or in the aggregate) in which the failure to be so qualified will not have or reasonably
be expected not to have a Material Adverse Effect. 

 

The Subsidiary is a
direct subsidiary of the Company. The Company (i) owns, directly or indirectly, all of the capital stock or other equity interests
of each Subsidiary free and clear of any Liens (as such term is defined below), and (ii) all of the issued and outstanding shares
of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights
to subscribe for or purchase securities, except as otherwise described in the Registration Statement and the Prospectus.

 

(b) Authorization;
Enforcement.  The Company has the requisite corporate power and authority to enter into and perform this Agreement
and to issue and sell the Shares in accordance with the terms hereof (and to issue the Common Stock issuable upon conversion of
the Shares) and to file the Certificate of Designation.  The execution, delivery and performance of this Agreement by
the Company, the consummation by it of the transactions contemplated hereby and the filing of the Certificate of Designation have
been duly and validly authorized by all necessary action on the part of the Company, and no further action, consent or authorization
of the Company or its Board of Directors or stockholders is required in connection therewith.  Each Transaction Document
to which it is a party has been (or upon delivery will have been) duly executed and delivered by the Company.  Each Transaction
Document, and the Shares, constitute the valid and binding obligations of the Company enforceable against the Company in accordance
with their terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s
rights and remedies or by equitable principles of general application and insofar as indemnification and contribution provisions
may be limited by applicable law.

 

    	- 5 -

    	 

    

 

(c) Capitalization.  As
of [•] but prior to the issuance of any Shares pursuant to this Agreement, the authorized capital stock of the Company consists
of [•] shares of Common Stock, of which [•] are issued and outstanding, [•] shares of Series A Convertible Preferred
Stock, of which [•] are issued and outstanding, [•] shares of Series B Preferred Stock, of which [•] are issued
and outstanding, [•] shares of Series C Convertible Preferred Stock, of which [•] are issued and outstanding, and [•]
shares of authorized preferred stock, none of which are issued and outstanding. All of the issued shares of capital stock of the
Company have been duly and validly authorized and issued, are fully paid and non-assessable, have been issued in compliance with
federal and state securities laws.

 

The Articles of Incorporation
and Bylaws of the Company, each amended to date, currently on file with the Commission (as so amended, the “Charter Documents”)
are true and correct.  All of the outstanding shares of capital stock of the Company have been duly and validly authorized
and are fully paid and non-assessable.  None of the Shares (or shares of Common Stock issuable upon conversion of the
Shares) are subject to preemptive rights, except as otherwise described in the Registration Statement and the Prospectus.  The
Company is not a party to, and it has no knowledge of, any agreement restricting the voting of any shares of its common stock or
restricting the transfer of its securities.

 

The Company has not
issued any capital stock since its most recently filed report under the Exchange Act, other than
pursuant to the exercise of stock options under the Company’s stock option plans, the issuance of shares of Common Stock
to employees pursuant to the Company’s employee stock purchase plans and pursuant to the conversion and/or exercise of common
stock equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. Except as set forth
in that certain Securities Purchase Agreement dated July 10, 2012 (the “July 10 Securities Purchase Agreement”),
no Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the
transactions contemplated by the Transaction Documents. Except as described in the Company’s SEC Reports, there are no outstanding
options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights
or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire,
any Shares or shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any subsidiary
is or may become bound to issue additional Shares or shares of Common Stock or common stock equivalents, other than as a result
of the purchase and sale of the Shares or the conversion of the Shares. Except as disclosed in the Registration Statement and in
the July 10 Securities Purchase Agreement, the issuance and sale of the Shares, and the issuance of Common Stock upon conversion
of the Shares, will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than the
Purchasers) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or
reset price under any of such securities. No further approval or authorization of any stockholder, the Board of Directors or others
is required for the issuance and sale of the Shares or the conversion of the Shares into Common Stock. There are no stockholders
agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company
is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders that are not described
in the SEC Reports.

 

    	- 6 -

    	 

    

 

(d) Issuance of
the Shares; Registration.  At Closing, the Shares to be sold to the Purchaser (and the shares of Common Stock issuable
upon conversion thereof) will be duly and validly authorized by all necessary corporate action and, when the Shares are paid for
in accordance with the terms hereof (and when the shares of Common Stock are issued upon conversion of the Shares), will be validly
issued and outstanding, fully paid and non-assessable shares of the capital stock of the Corporation. The Company has reserved
from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant to this Agreement and the
Shares. The Company has prepared and filed the Registration Statement in conformity with the requirements of the Securities Act,
which became effective on _________________ (the “Effective Date”), including the Prospectus contained therein
at the time of effectiveness (the “Prospectus”), and such amendments and supplements thereto as may have been
required to the Effective Date. The Registration Statement is effective under the Securities Act and no stop order preventing or
suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has been issued
by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened
by the Commission. At the time the Registration Statement and any amendments thereto became effective, and at the Closing Date,
the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of
the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments
or supplements thereto, at time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed
and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading. The Company meets all of the requirements for the use of Form S-1 under
the Securities Act for the offering and sale of the Shares contemplated by this Agreement and the other Transaction Documents,
and the Commission has not notified the Company of any objection to the use of the form of the Registration Statement pursuant
to Rule 401(g)(1) under the Securities Act. The Registration Statement meets the requirements set forth in Rule 415(a)(1)(x) under
the Securities Act. The Company and the Placement Agent have made or caused to be made all filings required to be made with the
Financial Industry Regulatory Authority in connection with the offer and sale of the Shares hereunder.

 

(e) No Conflicts.  The
execution, delivery and performance of this Agreement by the Company, and the performance by the Company of its obligations contemplated
herein and under the Transaction Documents do not and will not (i) violate any provision of the Charter Documents, (ii) conflict
with, or constitute a default under any material agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement,
instrument or obligation to which the Company is a party, or (iii) create or impose a lien, mortgage, security interest, charge
or encumbrance of any nature on any property of the Company under any agreement or any commitment to which the Company is a party
or by which the Company is bound or by which any of its respective properties or assets are bound, except, with respect to clauses
(ii) and (iii) above, to the extent any such contravention would not result in a Material Adverse Effect.

 

(f) Financial Statements.  The
Company’s audited financial statements for the fiscal years ended December 31, 2011 and 2010, and unaudited financial statements
for the three and nine months ended September 30, 2012 and 2011 on file with the Commission have been prepared in accordance with
accounting principles generally accepted in the United States (“GAAP”) applied on a consistent basis during
the periods involved (except as may be otherwise indicated in such financial statements or the notes thereto).  Since
the date of the latest audited financial statements on file with the Commission, except as specifically disclosed in a subsequent
SEC Report (as defined below) filed prior to the date hereof, (i) there has been no event, occurrence or development that has had
or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities
(contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent
with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP
or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company
has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made
any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to
any officer, director or Affiliate, except pursuant to existing Company stock option plans.

 

(g) Title to Assets.  The
Company has good and marketable title to all of its owned real and personal property whether tangible or intangible (collectively,
the “Assets”), free and clear of any mortgages, pledges, charges, liens, security interests, claim, community
property interest, condition, equitable interest or other encumbrances, license, option, right of first refusal or restriction
of any kind, including any restriction on use, voting, transfer, receipt of income or exercise of any other attribute of ownership
(“Liens”), except as described in the Registration Statement and the Prospectus.

 

    	- 7 -

    	 

    

 

(h) Taxes.  The
Company has accurately prepared and filed all material foreign, federal, state income and all other tax returns, reports and declarations
required by law to be paid or filed by it by any jurisdiction to which the Company is subject.  The Company has no knowledge
of any assessments, adjustments or contingent tax liability (whether federal or state) of any nature whatsoever, whether pending
or threatened against the Company for any period, nor of any basis for any such assessment, adjustment or contingency.  The
Company has complied in all material respects with all applicable legal requirements relating to the payment and withholding of
taxes and, within the time and in the manner prescribed by law, has withheld from wages, fees and other payments, and paid over
to the proper governments or regulatory authorities, all amounts required.

 

(i) Filings, Consents
and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or
make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person
in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to Section 4.1 of this Agreement, (ii) the filing with the Secretary of State of Nevada of the Certificate of
Designation, or (iii) such filings as are required to be made under applicable state securities laws.

 

(j) SEC Reports.
The Company has filed with the Commission all reports, schedules, forms, statements and other documents required to be filed by
the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, since January
1, 2010 (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with
the Prospectus, being collectively referred to herein as the “SEC Reports”) on a timely basis. As of their respective
dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable,
and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading.

 

(k) Material
Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included
within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the Effective Date or in the
Registration Statement, (i) there has been no event, occurrence or development that has had or that could reasonably be expected
to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than
(A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and settlement
agreements related to liabilities and (B) liabilities not required to be reflected in the Company’s financial statements
pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting,
(iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased,
redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity
securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. Except for confidential
treatment requests described in the SEC Reports, the Company does not have pending before the Commission any request for confidential
treatment of information. Except for the issuance of the Shares and Common Stock contemplated by this Agreement, no event, liability,
fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect
to the Company or its Subsidiary or their respective business, prospects, properties, operations, assets or financial condition
that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made
or deemed made that has not been publicly disclosed on or before the date that this representation is made.

 

    	- 8 -

    	 

    

 

(l) Litigation.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company,
threatened against or affecting the Company, its Subsidiary, or its properties before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state, county, local or foreign, including FINRA) (collectively, an
“Action”) which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction
Documents or the Shares or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material
Adverse Effect. None of the Company and its directors and officers, in their capacities as such, is or has been the subject of
any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary
duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission
or FINRA involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop
order or other order suspending the effectiveness of any registration statement filed by the Company under the Exchange Act or
the Securities Act.

 

(m) Disclosure.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company
confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel
with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed
in the Prospectus. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting
transactions in securities of the Company. All disclosures furnished by or on behalf of the Company to the Purchasers regarding
the Company, its business and the transactions contemplated hereby are true and correct and did not and do not contain any untrue
statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light
of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during the twelve
months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations
or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.

 

(n) Regulatory Permits.
Except as set forth in the SEC Reports, the Company and the Subsidiary possess all certificates, authorizations and permits issued
by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as
described in the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a
Material Adverse Effect (“Material Permits”), and neither the Company nor any subsidiary has received any notice
of proceedings relating to the revocation or modification of any Material Permit.

 

(o) Title to Assets.
The Company and its Subsidiary have good and marketable title in fee simple to all real property owned by them and good and marketable
title to all personal property owned by them that is material to the business of the Company and its Subsidiary, in each case free
and clear of all Liens, except for Liens as do not materially affect the value of such property and do not materially interfere
with the use made and proposed to be made of such property by the Company and its Subsidiary and Liens for the payment of federal,
state or other taxes, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held
under lease by the Company and its Subsidiary are held by them under valid, subsisting and enforceable leases with which the Company
and its Subsidiary are in compliance with such exceptions as are not material and do not materially interfere with the use made
and proposed to be made of such property and facilities by the Company and its Subsidiary.

 

    	- 9 -

    	 

    

 

(p) No Integrated
Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2, neither the
Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or
sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Shares
to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading
Market on which any of the securities of the Company are listed or designated.

 

(q) Patents and
Trademarks. To the knowledge of the Company, the Company owns or has the right to use all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property
rights and similar rights necessary or material for use in connection with its business (collectively, the “Intellectual
Property Rights”). Except as otherwise disclosed in writing to the Placement Agent, (i) the Company has not received
a notice (written or otherwise) that any of the Intellectual Property Rights used by the Company violates or infringes upon the
rights of any Person and (ii) the Company is unaware of any infringement by a third party of any of the Company’s Intellectual
Property Rights. To the knowledge of the Company, all of its Intellectual Property Rights are enforceable. The Company and its
Subsidiary have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual
property. 

 

(r) Insurance.
The Company and its Subsidiary are insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as are prudent and customary in the businesses in which the Company and its Subsidiary are engaged, including,
but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the
Company nor any subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without
a significant increase in cost.

 

(s) Transactions
With Affiliates and Employees. Except as set forth in the SEC Reports, none of the officers or directors of the Company and,
to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company
or any subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement
providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring
payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer,
director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess
of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred
on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the
Company.

 

(t) Sarbanes-Oxley.
The Company is in material compliance with all provisions of the Sarbanes-Oxley Act of 2002 that are applicable to it as of the
Closing Date.

 

(u) Certain
Fees. Except as set forth in the Placement Agent Agreement, no brokerage or finder’s fees or commissions are or will
be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other
Person with respect to the transactions contemplated by the Transaction Documents. The Purchaser shall have no obligation with
respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this
Section that may be due in connection with the transactions contemplated by the Transaction Documents.

 

    	- 10 -

    	 

    

 

(v) Investment
Company. The Company is not, and immediately after receipt of payment for the Shares, will not be an “investment company”
within the meaning of the Investment Company Act of 1940, as amended.

 

(w) Registration
Rights. Except as set forth in the SEC Reports, no Person has any right to cause the Company to effect the registration under
the Securities Act of any securities of the Company as a result of the transactions contemplated by this Agreement.

 

(x) Listing
and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the
Company has taken no action designed to, or that to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding the Effective Date,
received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company
is not in compliance with the listing or maintenance requirements of such Trading Market. Except as disclosed in the SEC Reports,
the Company is in compliance with all such listing and maintenance requirements.

 

(y) Application
of Takeover Protections. The Company and the Board of Directors have taken all necessary action, if any, in order to render
inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company’s certificate of incorporation (or similar charter documents)
or the laws of its state of incorporation that is or could become applicable to the Purchaser as a result of the Purchaser and
the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including, without limitation
as a result of the Company’s issuance of the Shares and Common Stock and the Purchaser’s ownership of the Shares and
Common Stock.

 

(z) Disclosure.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company
confirms that neither it nor any other Person acting on its behalf has provided the Purchaser or its agents or counsel with any
information that it believes constitutes or might constitute material, non-public information. The Company understands and confirms
that the Purchaser will rely on the foregoing representation in effecting transactions in securities of the Company. The Company
acknowledges and agrees that the Purchaser does not make or has not made any representations or warranties with respect to the
transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.

 

(aa) Foreign
Corrupt Practices. Neither the Company, nor to the knowledge of the Company, any agent or other person acting on behalf of
the Company, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful
expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials
or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully
any contribution made by the Company (or made by any person acting on its behalf of which the Company is aware) which is in violation
of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.

 

(bb) Accountants.
The Company’s independent registered public accounting firm is identified in the Prospectus and such accounting firm is a
registered public accounting firm as required by the Exchange Act.

 

    	- 11 -

    	 

    

 

(cc) Acknowledgment
Regarding Purchaser’s Purchase of Securities. The Company acknowledges and agrees that the Purchaser is acting solely
in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that the Purchaser is not acting as a financial advisor or fiduciary of the Company (or
in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given
by the Purchaser or any of its respective representatives or agents in connection with the Transaction Documents and the transactions
contemplated thereby is merely incidental to the Purchaser’s purchase of the Shares. The Company further represents to the
Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents has been based solely
on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

 

(dd) Acknowledgement
Regarding Purchaser’s Trading Activity. Anything in this Agreement or elsewhere herein to the contrary notwithstanding
Regulation M adopted by the SEC, it is understood and acknowledged by the Company that: (i) the Purchaser has not been asked by
the Company to agree, nor has the Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the
Company, or “derivative” securities based on securities issued by the Company or to hold the Securities for any specified
term; (ii) past or future open market or other transactions by the Purchaser, specifically including, without limitation, Short
Sales or “derivative” transactions, before or after the closing of this or future private placement transactions,
may negatively impact the market price of the Company’s publicly-traded securities; (iii) the Purchaser, and counter-parties
in “derivative” transactions to which the Purchaser is a party, directly or indirectly, presently may have a “short”
position in the Common Stock, and (iv) the Purchaser shall not be deemed to have any affiliation with or control over any arm’s
length counter-party in any “derivative” transaction. The Company further understands and acknowledges that
(y) the Purchaser may engage in hedging activities at various times during the period that the Shares are outstanding, including,
without limitation, during the periods that the value of the Common Stock deliverable with respect to Shares are being determined,
and (z) such hedging activities (if any) could reduce the value of the existing stockholders’ equity interests in the Company
at and after the time that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging
activities do not constitute a breach of any of the Transaction Documents.

 

(ee) Regulation
M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Shares (including any Common Stock), (ii) sold, bid for, purchased, or, paid any compensation
for soliciting purchases of, any of the Shares (including any Common Stock), or (iii) paid or agreed to pay to any Person any compensation
for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation
paid to the Placement Agent in connection with the placement of the Shares.

 

(ff) FDA.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged,
labeled, tested, distributed, sold, and/or marketed by the Company or its Subsidiary (each such product, a “Product”),
except as described in the SEC Reports, such Product is being manufactured, packaged, labeled, tested, distributed, sold and/or
marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations, to the
extent applicable to the Company’s business as presently conducted, except where the failure to be in compliance would not
reasonably be expected to have a Material Adverse Effect. None of the Company or its Subsidiary has received any notice, warning
letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure,
registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of,
or the labeling and promotion of any Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or
withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Product, (iii) imposes a clinical
hold on any clinical investigation by the Company or its Subsidiary, (iv) enjoins production at any facility of the Company or
its Subsidiary, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or its Subsidiary,
or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or its Subsidiary, and which, either individually
or in the aggregate, would reasonably be expected to have a Material Adverse Effect. The properties, business and operations of
the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations
of the FDA. Except as described in the SEC Reports, the Company has not been informed by the FDA that the FDA will prohibit the
marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company.

 

    	- 12 -

    	 

    

 

(gg) Regulation
M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of,
any of the Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with
the placement of the Shares.

 

3.2. Representations
and Warranties of the Purchasers.  Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants
as of the date hereof and as of the Closing Date to the Company as follows:

 

(a) Organization;
Authority.  Such Purchaser, if an entity, is an entity duly incorporated or formed, validly existing and in good
standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by this Agreement
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and performance
by such Purchaser of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of such Purchaser.  Each Transaction Document
to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms
hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its
terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.

 

(b) Understandings
or Arrangements.  Such Purchaser is acquiring the Shares as principal for its own account and has no direct or indirect
arrangement or understandings with any other persons to distribute or regarding the distribution of such Shares (this representation
and warranty not limiting such Purchaser’s right to sell the Shares in compliance with applicable federal and state securities
laws).  Such Purchaser is acquiring the Shares hereunder in the ordinary course of its business.

 

(c) Trading Activities.  The
Purchaser’s trading activities with respect to the Shares shall be in compliance with all applicable federal and state securities
laws.  

 

    	- 13 -

    	 

    

 

(d) Estimates; Forward-Looking
Statements. The Purchaser acknowledges that any and all estimates or forward-looking statements or projections with which it
may have been provided (collectively, the “Information”) were prepared by the Company in good faith, but that
the attainment of any such projections, estimates or forward-looking statements cannot be guaranteed, will not be updated by the
Company and should not be relied upon. The Purchaser further acknowledges that any and all information regarding the historical
performance of the Company is not necessarily indicative of future performance.

 

(e) No Representations.  No
oral or written representations have been made, or oral or written information furnished, to the Purchaser or its advisors, if
any, in connection with the offering of the Shares which are in any way inconsistent with the information contained in the Prospectus.

 

ARTICLE IV.

 

OTHER AGREEMENTS OF THE PARTIES

 

4.1. Securities
Laws Disclosure; Publicity.  The Company shall (a) by 9:00 a.m. (Eastern time) on the Trading Day immediately following
the date hereof, issue a press release disclosing the material terms of the transactions contemplated hereby, and (b) file a Form
8-K, including the Transaction Documents as exhibits thereto, with the Commission within the time required by the Exchange Act.
Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser
in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser,
except (a) as required by federal securities law in connection with the filing of final Transaction Documents (including signature
pages thereto) with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations.

 

4.2. Indemnification
of Purchasers.   Subject to the provisions of this Section 4.2, the Company will indemnify and hold each Purchaser
and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles
notwithstanding a lack of such title or any other title) of such controlling persons (each, a “Purchaser Party”)
harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments,
amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser
Party may suffer or incur (but specifically excluding any incidental, indirect, punitive, special or
consequential damages) as a result of or relating to any breach of any of the representations, warranties, covenants or
agreements made by the Company in this Agreement or in the other Transaction Documents.

 

4.3. Equal Treatment
of Purchasers.  No consideration (including any modification of any Transaction Document) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of this Agreement or under any Transaction Document
unless the same consideration is also offered to all of the parties affected by such amendment or consent.  For clarification
purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each
Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers
acting in concert or as a group with respect to the purchase, disposition or voting of Shares or otherwise.

 

    	- 14 -

    	 

    

 

4.4. Certain
Transactions and Confidentiality. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither
it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company’s securities during the period commencing with the execution of this Agreement and ending
at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in Section 4.1.  Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such
time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release
as described in Section 4.1, such Purchaser will maintain the confidentiality of the existence and terms of this transaction. 

 

4.5. Shares.
If all or any portion of a Share is exercised at a time when there is an effective registration statement to cover the issuance
of the Common Stock issuable upon conversion of the Shares, the Common Stock issued pursuant to any such exercise shall be issued
free of all legends. If at any time following the Effective Date the Registration Statement (or any subsequent registration statement
registering the issuance of the Common Stock) is not effective or is not otherwise available for the issuance of the Common Stock,
the Company shall immediately notify the holders of the Shares in writing that such registration statement is not then effective
and thereafter shall promptly notify such holders when the registration statement is effective again and available for the issuance
of the Common Stock (it being understood and agreed that the foregoing shall not limit the ability of the Company to issue, or
the Purchaser to sell, any of the Shares in compliance with applicable federal and state securities laws). The Company shall use
its best efforts to keep a registration statement (including the Registration Statement) registering the issuance of the Common
Stock issuable upon conversion of the Shares effective during the term of the Shares are outstanding.

 

4.6. Furnishing
of Information. Until the date on which no Shares are outstanding, the Company shall timely file all reports required to be
filed with the Commission pursuant to the Exchange Act, and the Company shall not terminate its status as an issuer required to
file reports under the Exchange Act even if the Exchange Act or the rules and regulations thereunder would no longer require or
otherwise permit such termination.

 

4.7. Integration.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined
in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Shares or the Common Stock for purposes
of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such
other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.

 

4.8. Shareholder
Rights Plan. To the extent permitted by law, no claim will be made or enforced by the Company or, with the consent of
the Company, any other Person, that the Purchaser is an “Acquiring Person” under any control share
acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover
plan or arrangement in effect or hereafter adopted by the Company, or that the Purchaser could be deemed to trigger the
provisions of any such plan or arrangement, by virtue of receiving Shares and Common Stock under the Transaction Documents or
under any other agreement between the Company and the Purchaser.

 

4.9.
Use of Proceeds. The Company shall use the net proceeds from the sale of the Securities as provided in the Prospectus.

 

4.10. Reservation
of Common Stock. As of the Effective Date, the Company has reserved and the Company shall continue to reserve and keep available
at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company
to issue Shares pursuant to this Agreement and Common Stock pursuant to any conversion of the Shares (without regard to any limitations
on the exercise of the Shares set forth therein).

 

    	- 15 -

    	 

    

 

4.11. Listing
of Common Stock. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on
the Trading Market on which it is currently listed, and the Company shall promptly secure the listing of all of the Common Stock
on such Trading Market (but in no event later than the Closing Date). The Company further agrees, if the Company applies to have
the Common Stock traded on any other Trading Market, it will then include in such application the Common Stock, and will take such
other action as is necessary to cause all of the Common Stock to be listed or quoted on such other Trading Market as promptly as
possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on
a Trading Market and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws
or rules of the Trading Market.

 

4.12.
Placement Agent. In consideration for acting as placement agent in connection with the sale of the Shares
hereunder, the Placement Agent shall receive a commission of four percent (4%) of the gross proceeds raised in this offering
of Shares plus a non-accountable expense allowance of 1% of such proceeds.

 

ARTICLE V.

 

MISCELLANEOUS

 

5.1. Termination. This
Agreement may be terminated by any Purchaser, as to such Purchaser’s obligations hereunder only and without any effect whatsoever
on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not
been consummated on or before [ ● ]; provided, however, that no such termination will affect the
right of any party to sue for any breach by any other party (or parties).

 

5.2. Fees and
Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses
of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the
negotiation, preparation, execution, delivery and performance of this Agreement.  The Company shall pay all Transfer
Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the
Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the
delivery of any Shares to the Purchasers.

 

5.3. Entire
Agreement. The Transaction Documents, together with the exhibits and schedules thereto, the Pricing Prospectus, and the
Prospectus, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede
all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been
merged into such documents, exhibits and schedules.

 

5.4. Notices.  Any
and all notices or other communications or deliveries required or permitted to be provided hereunder by the Company to a Purchaser
shall be in writing and shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or
communication is delivered via fax at the fax number set forth on the signature pages attached hereto at or prior to 5:30 p.m.
(Eastern time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered
via fax at the fax number set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30
p.m. (Eastern time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally
recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given.  The
address for such notices and communications to the Purchasers shall be as set forth on the signature pages attached hereto.

    	- 16 -

    	 

    

 

Any notice required
or permitted to be provided hereunder by the Company to any Purchaser shall include a copy to counsel to the lead investor:

 

Sichenzia Ross
Friedman Ference, LLP

61 Broadway, Suite
3200

New York, NY 10006

(212) 930-9700

(212) 930-9725
(fax)

Attn: Harvey Kesner,
Esq.

Hkesner@srff.com

 

5.5. Amendments;
Waivers.  No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and the Purchasers holding at least a majority in interest of the Shares based
on the initial Subscription Amounts hereunder held by Purchasers as of the date of such waiver, modification, supplement or amendment.
No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof,
nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.

 

5.6. Headings.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.

 

5.7.  Successors
and Assigns.  This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns.  The Company may not assign this Agreement or any rights or obligations hereunder without the prior
written consent of each Purchaser (other than by merger).  Any Purchaser may assign any or all of its rights under this
Agreement to any Person to whom such Purchaser assigns or transfers any Shares, provided that such transferee agrees in writing
to be bound, with respect to the transferred Shares, by the provisions of the Transaction Documents that apply to the “Purchasers.”

 

5.8. No Third-Party
Beneficiaries.  This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise
set forth in Section 4.2 and this Section 5.8.

 

5.9. Governing
Law.  All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to
the principles of conflicts of law thereof.  Each party agrees that all legal proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought
against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents)
shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits
to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication
of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with
respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is improper or is an inconvenient venue for such proceeding.  Each party hereby irrevocably waives
personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof
via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices
to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.  If
either party shall commence an action, suit or proceeding to enforce any provisions of the Transaction Documents, then the prevailing
party in such action, suit or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other
costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

 

    	- 17 -

    	 

    

 

5.10. Survival.  The
representations and warranties contained herein shall survive the Closing and the delivery of the Shares.

 

5.11. Execution.  This
Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood
that the parties need not sign the same counterpart.  In the event that any signature is delivered by fax or by e-mail
delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing
(or on whose behalf such signature is executed) with the same force and effect as if such fax or “.pdf” signature page
were an original thereof.

 

5.12. Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.

 

5.13. Remedies.  In
addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the
Purchasers and the Company will be entitled to specific performance under the Transaction Documents.  The parties agree
that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in
the Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation
the defense that a remedy at law would be adequate. Notwithstanding anything to the contrary contained in (and without limiting
any similar provisions of) any of the other Transaction Documents, whenever the Purchaser exercises a right, election, demand or
option under a Transaction Document (other than under the Subscription Agreement with respect to the purchase of the Shares) and
the Company does not timely perform its related obligations within the periods therein provided, then the Purchaser may rescind
or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election
in whole or in part without prejudice to its future actions and rights; provided, however, that in the case of a rescission of
an conversion of Shares, the Company shall return to the Purchaser any aggregate exercise, conversion or other purchase price paid
to the Company with respect to such conversion and the Company shall restore the Purchaser’s right to acquire the shares
of Common Stock pursuant to the conversion of Purchaser’s Shares (including, issuance of a replacement Share certificate
evidencing such restored right).  For the absence of doubt, nothing contained in this Section 5.13 shall authorize or permit
the Purchaser to rescind or withdraw the Purchaser’s obligation to purchase or the Company’s agreement to accept the
purchase of Shares under the Subscription Agreement, which obligations shall not be subject to any rescission right of the Purchaser.
For the avoidance of doubt, the Purchaser shall not have any rescission or withdrawal rights under this Section 5.13, for a conversion
request (and only for such particular conversion request) if the Company issues and delivers shares of its Common Stock to the
Purchaser prior to the Purchaser’s invocation of such rescission or withdrawal rights. Notwithstanding the foregoing, the
invocation or lack of invocation of any Purchaser’s rescission or withdrawal rights under this Section 5.13, shall not prohibit
or affect such Purchaser’s rights under this Section 5.13 relating to any subsequent conversion request.

 

    	- 18 -

    	 

    

 

5.14. Independent
Nature of Purchasers’ Obligations and Rights.  The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the
performance or non-performance of the obligations of any other Purchaser under any Transaction Document.  Each Purchaser
has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents.

 

5.15. Saturdays,
Sundays, Holidays, etc.  If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next
succeeding Business Day.

 

5.16. WAIVER OF JURY
TRIAL.  IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES
EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

 

[Signature pages immediately follow.]

 

    	- 19 -

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Subscription Agreement to be duly executed by their respective authorized signatories as of
the date first indicated above.

 

	MUSCLEPHARM CORPORATION	 
	 	 
	By:	 	 
	 	Name: Brad J. Pyatt	 
	 	Title: Chief Executive Officer and President	 
	 	 
	Address for notice:	 
	[•]	 
	Attention: [•]	 
	 	 
	With a copy to (which shall not constitute notice):	 
	 	 
	[•]	 

 

[Purchaser signature pages immediately
follow.]

 

    	- 20 -

    	 

    

 

[Purchaser signature
pages to MusclePharm Corporation Subscription Agreement]

 

IN WITNESS WHEREOF,
the undersigned have caused this Subscription Agreement to be duly executed by their respective authorized signatories as of the
date first indicated above.

 

Subscription Amount: $ _____________

 

No. of Shares of Series D Convertible Preferred
Stock: _____________________

 

Name of Purchaser: ________________________________________________________

 

Signature of Authorized Signatory of Purchaser:
_________________________________

 

Name of Authorized Signatory: _______________________________________________

 

Title of Authorized Signatory: ________________________________________________

 

Email Address of Authorized Signatory:_________________________________________

 

Fax Number of Authorized Signatory: __________________________________________

 

Soc. Sec./Tax ID No.: _______________________________________________________

 

Address for Notice to Purchaser:

 

__________________________

 

__________________________

 

Address for Delivery of Shares of Series
D Convertible Preferred Stock to Purchaser (if not same as address for notice):

 

_________________________

 

    	- 21 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}]]